June 7, 2025 06:00 AM EDT
Weekly

High­lights from #AS­CO25; Biotech’s icy mar­ket; Sanofi’s $9B ac­qui­si­tion; and more

Max Gelman

Senior Editor

Hap­py Sat­ur­day, dear read­ers! It’s an­oth­er edi­tion of End­points Week­ly, your one-stop shop for all of the week’s biggest bio­phar­ma news. So grab a cup …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

Bio­phar­ma lead­ers carv­ing a path for the in­dus­try’s LGBTQ+ com­mu­ni­ty

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times